The Royal Marsden NHS Foundation Trust (RM)
Welcome,         Profile    Billing    Logout  
 52 Trials 
141 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cameron, David
TACT2, NCT00301925: Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery

Active, not recruiting
3
4400
Europe
pegfilgrastim, capecitabine, cyclophosphamide, epirubicin hydrochloride, fluorouracil, methotrexate, adjuvant therapy
Institute of Cancer Research, United Kingdom
Breast Cancer
09/24
09/24
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
SL03-OHD-105, NCT05483933: Phase 1b Study of SL-172154 Administered with Combination Agent(s) in Subjects with Ovarian Cancers

Active, not recruiting
1
86
Europe, Canada, US
Pegylated Liposomal Doxorubicin + SL-172154, Doxil, PLD, Caelyx, Mirvetuximab + SL-172154, IMGN853, MIRV
Shattuck Labs, Inc.
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Primary Peritoneal Carcinoma
11/24
11/24
Roylance, Rebecca
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
PARTNER, NCT03150576: Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Recruiting
2/3
780
Europe
Olaparib, Lynparza, Paclitaxel and Carboplatin, Taxol and Paraplatin
Cambridge University Hospitals NHS Foundation Trust, AstraZeneca, Cancer Research UK
Breast Cancer
06/24
06/34
ROLo, NCT03620643 / 2017-001680-20: Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

Active, not recruiting
2
58
Europe
Crizotinib Oral Capsule [Xalkori], Xalkori, Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic], Faslodex
Royal Marsden NHS Foundation Trust, Pfizer, Breast Cancer Now
Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer, CDH1 Gene Mutation
07/24
07/24
FAIM, NCT04920708: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Recruiting
2
324
Europe
Ipatasertib 300mg, RG7440, Fulvestrant 500g, Faslodex, Palbociclib 75mg-125mg, Ibrance, CDK4/6 Inhibitor, Abemaciclib / Ribociclib / Palbociclib
Royal Marsden NHS Foundation Trust, Pfizer, Hoffmann-La Roche
Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
09/26
09/26
TRAK-ER, NCT04985266 / 2020-004022-36: A Trial of Early Detection of Molecular Relapse With Circulating Tumour DNA Tracking and Treatment With Palbociclib Plus Fulvestrant Versus Standard Endocrine Therapy in Patients With ER Positive HER2 Negative Breast Cancer

Recruiting
2
1100
Europe
Palbociclib 125Mg Tab, Fulvestrant injection, Tamoxifen, Letrozole, Exemestane, Anastrozole
Royal Marsden NHS Foundation Trust, Pfizer, AstraZeneca, Institute of Cancer Research, United Kingdom, UNICANCER, Gustave Roussy, Cancer Campus, Grand Paris, Invitae Corporation
ER+ Breast Cancer, HER2-negative Breast Cancer
09/27
09/30
ELEVATE, NCT05563220: Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

Recruiting
1/2
400
Europe, US, RoW
Elacestrant, Alpelisib, Piqray, Everolimus, Afinitor, Ribociclib, Kisqali, Palbociclib, Ibrance, Capivasertib, Truqap, Abemaciclib, Verzenio
Stemline Therapeutics, Inc.
Breast Cancer, Metastatic Breast Cancer
12/24
08/26
PAveMenT, NCT04360941: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Recruiting
1
45
Europe
Palbociclib, Ibrance, Avelumab, Bavencio
Royal Marsden NHS Foundation Trust, Pfizer, Breast Cancer Now
Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer
07/25
12/25
Cirauqui, Beatriz
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
Huang, Chiun-Sheng
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
NCT04046159: Radiotherapy Versus Low-Dose Tamoxifen Following Breast Conserving Surgery for Low-Risk Breast Ductal Carcinoma in Situ

Recruiting
3
810
RoW
Low-dose tamoxifen, LDT, Whole breast radiotherapy, WBRT
National Taiwan University Hospital, Tri-Service General Hospital, Koo Foundation Sun Yat-Sen Cancer Center, Kaohsiung Medical University, Kyoto University, Mackay Memorial Hospital
Breast Ductal Carcinoma in Situ
12/25
12/25
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Cornerstone001, NCT05163223: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer

Terminated
2
10
US, RoW
AST-301(pNGVL3-hICD), AST-301, rhuGM-CSF, Leukine, Sargramostim, Placebo, Normal Saline, Pembrolizumab, Keytruda, Capecitabine, Xeloda
Aston Sci. Inc.
Breast Cancer
05/24
05/24
RCENSM-P, NCT04037852: Robotic Versus Conventional or Endoscopic Nipple Sparing Mastectomy in the Management of Breast Cancer-Prospective Study

Recruiting
N/A
180
RoW
robotic assisted nipple sparing mastectomy, Endoscopic assisted nipple sparing mastectomy, Conventional nipple sparing mastectomy
Changhua Christian Hospital, Intuitive Surgical, Ministry of Science and Technology, Taiwan
Breast Cancer Female
12/21
02/22
EXPERT, NCT02889874: EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer

Recruiting
N/A
1167
Europe, RoW
Omission of radiation therapy
Breast Cancer Trials, Australia and New Zealand, Breast International Group, ETOP IBCSG Partners Foundation
Early Stage Breast Carcinoma
10/25
04/26
Herrero, Fernando
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene, Ltd.
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
NCT05983367: A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

Active, not recruiting
2
70
Europe
Ompenaclid, RGX-202-01, Placebo, Bevacizumab, FOLFIRI regimen
Inspirna, Inc.
Colorectal Cancer, Metastatic Colon Cancer
09/25
12/26
SGNB6A-001, NCT04389632: A Study of SGN-B6A in Advanced Solid Tumors

Recruiting
1
824
Europe, US, RoW
sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin
Seagen Inc.
Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
11/26
02/28
Awan, Arif
INVINCIBLE, NCT04781725: TRIAL: Intratumoral INT230-6 in Breast Cancer

Recruiting
2
90
Canada
INT230-6, Cisplatin, Vinblastine, 2-hydroxybenzoylaminooctanoate (SAHO), Saline injection
Ottawa Hospital Research Institute, Intensity Therapeutics, Inc., Ontario Institute for Cancer Research
Breast Cancer
03/22
03/23
KEYNOTE B81, NCT04609566: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors

Recruiting
2
140
Canada, US
brentuximab vedotin, ADCETRIS, pembrolizumab, KEYTRUDA®
Seagen Inc., Merck Sharp & Dohme LLC
Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
10/25
09/26
NCT05601440: Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer

Recruiting
2
484
Canada
RP-6306, Lunresertib, Gemcitabine, Observation, Niraparib, Fulvestrant, RP-3500, Camonsertib
Canadian Cancer Trials Group
Breast Cancer
12/27
06/28
NCT06157892: A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Recruiting
1/2
198
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, tucatinib, TUKYSA, ONT-380, ARRY-380
Seagen Inc., RemeGen Co., Ltd.
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
01/30
01/30
NCT06077877: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

Recruiting
1/2
135
Canada, US
GSK4524101, Niraparib
GlaxoSmithKline
Neoplasms
12/27
11/29
SGNALPV-001, NCT05229900: A Study of SGN-ALPV in Advanced Solid Tumors

Terminated
1
43
Europe, Canada, US
SGN-ALPV
Seagen Inc.
Ovarian Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Gastroesophageal Junction Carcinoma, Uterine Cervical Neoplasms, Testicular Neoplasms
12/23
12/23
SGNSTNV-001, NCT04665921: A Study of SGN-STNV in Advanced Solid Tumors

Terminated
1
111
Europe, Canada, US
SGN-STNV
Seagen Inc.
Carcinoma, Non-Small Cell Lung, HER2 Negative Breast Neoplasms, Ovarian Neoplasms, Uterine Cervical Neoplasms, Endometrial Neoplasms, Esophageal Neoplasms, Gastroesophageal Junction Carcinoma, Stomach Neoplasms, Colorectal Neoplasms, Exocrine Pancreatic Adenocarcinoma, Appendiceal Adenocarcinoma, Pseudomyxoma Peritonei
03/24
03/24
SGNB7H4V-001, NCT05194072: A Study of SGN-B7H4V in Advanced Solid Tumors

Active, not recruiting
1
572
Europe, Canada, US
SGN-B7H4V, Pembrolizumab, Keytruda
Seagen Inc.
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms, HER2 Negative Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Endometrial Neoplasms, Carcinoma, Non-Small-Cell Lung, Cholangiocarcinoma, Gallbladder Carcinoma, Adenoid Cystic Carcinoma
11/27
11/27
SGNBB228-001, NCT05571839: A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors

Recruiting
1
275
Europe, Canada, US
PF-08046049
Seagen Inc.
Cutaneous Melanoma, Non-small Cell Lung Cancer, Colorectal Neoplasms, Pancreatic Neoplasms, Mesothelioma
11/26
11/27
NCT04564079: An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network

Recruiting
N/A
100
Canada
Exactis Innovation
NSCLC
07/23
08/23
NCT02355171: Personalize My Treatment (PMT) Registry

Recruiting
N/A
10000
Canada
Exactis Innovation
Cancer
07/25
07/25
BEACON, NCT05804578: Using a Blood Test to Monitor Metastatic Breast Cancer Treatment

Recruiting
N/A
150
Canada
Dr. Christopher Mueller, Canadian Institutes of Health Research (CIHR), Queen's University
Metastatic Breast Cancer
01/26
04/26
Armstrong, Anne
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Calendar Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer
Active, not recruiting
3
43
Europe, Canada, Japan, US, RoW
Niraparib, Placebo
GlaxoSmithKline
Neoplasms, Breast
06/24
12/25
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
PARTNER, NCT03150576: Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer

Recruiting
2/3
780
Europe
Olaparib, Lynparza, Paclitaxel and Carboplatin, Taxol and Paraplatin
Cambridge University Hospitals NHS Foundation Trust, AstraZeneca, Cancer Research UK
Breast Cancer
06/24
06/34
ROLo, NCT03620643 / 2017-001680-20: Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

Active, not recruiting
2
58
Europe
Crizotinib Oral Capsule [Xalkori], Xalkori, Fulvestrant 50 MG/ML Prefilled Syringe [Faslodex or generic], Faslodex
Royal Marsden NHS Foundation Trust, Pfizer, Breast Cancer Now
Lobular Breast Carcinoma, Gastric Cancer, Triple Negative Breast Cancer, CDH1 Gene Mutation
07/24
07/24
IMpALA, NCT04188119: A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer

Not yet recruiting
2
42
NA
Avelumab, Bavencio, Aspirin, Lansoprazole
The Christie NHS Foundation Trust, University of Manchester
Breast Cancer
09/24
05/25
FAIM, NCT04920708: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression

Recruiting
2
324
Europe
Ipatasertib 300mg, RG7440, Fulvestrant 500g, Faslodex, Palbociclib 75mg-125mg, Ibrance, CDK4/6 Inhibitor, Abemaciclib / Ribociclib / Palbociclib
Royal Marsden NHS Foundation Trust, Pfizer, Hoffmann-La Roche
Metastatic Breast Cancer, ER+ Breast Cancer, Advanced Breast Cancer
09/26
09/26
PAveMenT, NCT04360941: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Recruiting
1
45
Europe
Palbociclib, Ibrance, Avelumab, Bavencio
Royal Marsden NHS Foundation Trust, Pfizer, Breast Cancer Now
Triple Negative Breast Cancer, Locally Advanced Breast Cancer, Recurrent Breast Cancer, Metastatic Breast Cancer, ER+ Breast Cancer, HER2-positive Breast Cancer
07/25
12/25
Montes, Ana
ICON9, NCT03278717 / 2017-000161-75: Study Evaluating the Efficacy of Maintenance Olaparib and Cediranib or Olaparib Alone in Ovarian Cancer Patients

Recruiting
3
330
Europe, Canada, RoW
Olaparib, Cediranib
University College, London, Cancer Research UK, AstraZeneca UK Limited
Ovarian Cancer
12/23
12/23
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
PREDICT 2X-121, NCT03878849: Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®

Active, not recruiting
2
60
Europe, US
2X-121, E7449, MGI25036, 2X-121 DRP®
Allarity Therapeutics, Alcedis GmbH, Amarex Clinical Research
Advanced Ovarian Cancer
09/24
03/25
Ganju, Vinod
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
DREAM3R, NCT04334759: DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma

Active, not recruiting
3
214
US, RoW
Durvalumab, MEDI4736, Imfinzi, Standard Chemotherapy, Cisplatin or Carboplatin and Pemetrexed, Ipilimumab and Nivolumab, Yervoy, Opdivo
PrECOG, LLC., AstraZeneca, Thoracic Oncology Group Australasia (TOGA), University of Sydney
Mesothelioma, Pleural Mesothelioma, Malignant Pleural Mesothelioma
06/25
02/26
INTEGRATEIIb, NCT04879368 / 2020-004617-12: RegoNivo vs Standard of Care Chemotherapy in AGOC

Active, not recruiting
3
450
Europe, Japan, US, RoW
Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf
Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health
Gastro-Oesophageal Cancer
06/25
06/26
SGNLVA-005, NCT04032704 / 2019-001946-17: A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

Terminated
2
205
Europe, US, RoW
ladiratuzumab vedotin, SGN-LIV1A, pembrolizumab, Keytruda
Seagen Inc., Merck Sharp & Dohme LLC
Small Cell Lung Cancer, Non-small Cell Lung Cancer, Squamous, Non-small Cell Lung Cancer, Non-squamous, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Prostate Cancer, Melanoma
11/23
11/23
ASCEND, NCT05042128: The Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruiting
2
158
RoW
LSTA1, CEND-1, certepetide, Gemcitabine Injection, Gemzar, Nab paclitaxel, Abraxane
Australasian Gastro-Intestinal Trials Group, University of Sydney
Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Cancer
06/25
10/25
SGNDV-005, NCT06003231: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Recruiting
2
160
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC
Seagen Inc.
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms
05/26
05/28
NCT04370587: A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

Recruiting
1/2
64
US, RoW
T3011, T3011 + pembrolizumab
ImmVira Pharma Co. Ltd
Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC
10/23
10/25
NCT04565275: A Study of ICP-192 in Patients With Advanced Solid Tumors

Recruiting
1/2
45
US, RoW
Drug ICP-192
Beijing InnoCare Pharma Tech Co., Ltd.
Advanced Solid Tumors, Urothelial Carcinoma, Cholangiocarcinoma
11/23
04/24
EIK1003-001, NCT06253130: A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Recruiting
1/2
70
US, RoW
IMP1734
Eikon Therapeutics, Impact Therapeutics, Inc.
Advanced Solid Tumor
02/26
12/26
NCT04618393: A Study of EMB-02 in Participants With Advanced Solid Tumors

Terminated
1/2
47
US, RoW
EMB-02
Shanghai EpimAb Biotherapeutics Co., Ltd.
Advanced Solid Tumors
07/23
03/24
NCT05188664: Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors

Terminated
1/2
20
RoW
LM-302, Toripalimab, Tuoyi
LaNova Australia Pty Limited
Advanced Solid Tumor
11/23
11/23
NCT06157892: A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors

Recruiting
1/2
198
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC, tucatinib, TUKYSA, ONT-380, ARRY-380
Seagen Inc., RemeGen Co., Ltd.
Breast Neoplasms, Gastroesophageal Junction Adenocarcinoma, HER2 Low Breast Neoplasms, HER2 Positive Breast Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms, Metastatic Breast Cancer, Metastatic Gastric Cancer, Advanced Breast Cancer, Advanced Gastric Cancer
01/30
01/30
AK104-212, NCT05505825: A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer

Active, not recruiting
1/2
36
RoW
AK104 IV infusion；Chiauranib oral
Akeso, Chipscreen Biosciences, Ltd.
SCLC,Extensive Stage
12/24
01/25
NCT04814875: A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy

Terminated
1/2
16
RoW
ATX-101 + Carboplatin + Pegylated liposomal doxorubicin (ACD)
THERAPIM PTY LTD, Novotech (Australia) Pty Limited
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, High Grade Serious or Endometrioid Carcinoma of the Ovary, Fallopian Tube, or Primary Peritoneal Cancer
11/23
11/23
SHR-A1904-I-104, NCT05277168: A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS

Recruiting
1/2
83
US, RoW
SHR-A1904
Jiangsu HengRui Medicine Co., Ltd.
Advanced Solid Tumors
03/26
05/26
NCT05910827: Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers

Recruiting
1/2
98
RoW
HMBD-001, Docetaxel, Cetuximab
Hummingbird Bioscience, Merck KGaA, Darmstadt, Germany
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Advanced Cutaneous Squamous Cell Carcinoma
03/26
03/26
NCT04840784: First-in Human (FIH) Trial of ETH-155008 in Subjects With B-NHL, CLL/SLL and AML

Terminated
1a/1b
9
RoW
ETH-155008, study drug
Shengke Pharmaceuticals Pty Ltd
NHL, Leukemia
05/23
05/23
NCT04737122: Study of LM-061 in Subjects in Advanced Tumors

Terminated
1
18
RoW
LM-061, Kinase inhibitor, Toripalimab
LaNova Medicines Limited
Advanced Tumours
07/22
12/22
NCT04215809 / 2020-002736-73: Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL

Recruiting
1
35
US, RoW
APG2575
Ascentage Pharma Group Inc.
CLL/SLL
03/25
06/26
PTX-100-PD-012017, NCT03900442: Phase 1 Study of PTX-100 in Patients With Advanced Malignancies With PTCL Expansion Cohort

Recruiting
1
24
RoW
PTX-100
Prescient Therapeutics, Ltd.
Advanced Cancer, PTCL
04/23
04/23
CI-8993-101, NCT04475523: Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies

Completed
1
26
US, RoW
CI-8993
Curis, Inc.
Solid Tumor
05/23
05/23
SHR-A1811-I-101, NCT04446260: A Study of SHR-A1811 in Subjects With Advanced Malignant Solid Tumors

Active, not recruiting
1
396
US, RoW
SHR-A1811
Jiangsu HengRui Medicine Co., Ltd., Atridia Pty Ltd.
Advanced Solid Tumors
12/25
03/26
NCT05198752: A Study of Neoantigen mRNA Personalised Cancer in Patients With Advanced Solid Tumors

Recruiting
1
30
Europe, RoW
Neoantigen mRNA Personalised Cancer SW1115C3
Stemirna Therapeutics
Solid Tumor
12/23
06/24
NCT05263180: A Study of EMB-09 in Participants With Advanced or Metastatic Solid Tumors.

Recruiting
1
30
RoW
EMB-09
Shanghai EpimAb Biotherapeutics Co., Ltd.
Advanced Solid Tumor
12/23
12/24
NCT05169697: A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors

Completed
1
6
RoW
A:YH002+YH001, B:YH002+YH001, YH002+YH001
Eucure (Beijing) Biopharma Co., Ltd
Advanced Solid Tumor
07/23
07/23
Argonaut, NCT05480865: SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation

Terminated
1
28
Europe, RoW
BBP-398, sotorasib
Navire Pharma Inc., a BridgeBio company, Amgen
Solid Tumor, Adult, Metastatic Solid Tumor, Metastatic NSCLC, Non Small Cell Lung Cancer
08/24
08/24
StingrayTx, NCT06063681: A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors

Recruiting
1
18
RoW
SR-8541A
Stingray Therapeutics
Advanced / Metastatic Solid Tumor
08/24
08/24
NCT06007482: A Study of ES009 in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
1
20
RoW
ES009
Elpiscience Biopharma Australia Pty. Ltd.
Advanced Solid Tumor
08/24
08/25
NCT06730386: A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors

Not yet recruiting
1
100
RoW
AK138D1
Akeso
Solid Cancer
02/28
08/28
NCT06560138: A Trial of SHR-4602 Infusion in Patients With SHR-4602 in Subjects With HER2-expressing or HER2-mutated Locally Advanced or Metastatic Solid Tumors

Withdrawn
1
20
RoW
SHR-4602
Atridia Pty Ltd.
HER2-expressing or HER2-mutated Locally or Metastatic Solid Tumors
12/25
09/26
NCT05872295: IKS014 in Advanced Solid Tumors That Express HER2

Recruiting
1
165
RoW
IKS014
Iksuda Therapeutics Ltd.
Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
09/25
09/27
DF6215-001, NCT06108479: Study of DF6215 in Patients With Advanced Solid Tumors

Recruiting
1
102
Europe, US, RoW
DF6215
Dragonfly Therapeutics
Solid Tumor, Adult
09/25
12/27
NCT06074497: This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors.

Recruiting
1
54
RoW
KGX101- Cohort -1, KGX101- Cohort 1, KGX101- Cohort 2, KGX101- Cohort 3, KGX101- Cohort 4, KGX101- Cohort 5, KGX101 and Envafolimab
Kangabio AUSTRALIA LTD PTY
Advanced or Metastatic Solid Tumors
05/26
05/26
Brana, Irene
OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting
2
194
Europe, US, RoW
ISA101b, Cemiplimab, Placebo
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive
09/24
06/25
KEYNOTE-E02, NCT03485209 / 2017-005076-26: Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Active, not recruiting
2
352
Europe, Canada, US
tisotumab vedotin, TIVDAK, pembrolizumab, KEYTRUDA®, carboplatin, cisplatin
Seagen Inc., Genmab, Merck Sharp & Dohme LLC
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Exocrine Pancreatic Cancer, Carcinoma, Squamous Cell of Head and Neck
02/26
11/26
ProcemISA, NCT04398524 / 2020-003652-32: A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC

Hourglass May 2024 - Jul 2024 : Mid'24 - Data from ISA101b-OPC-03-19 study in recurrent metastatic HPV16 induced HNC
Active, not recruiting
2
65
Europe, US, RoW
ISA101b, Cemiplimab
ISA Pharmaceuticals, Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Oropharynx
06/24
12/24
NCT05743270: Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN

Withdrawn
2
130
Europe, US, RoW
RP3, CCRT(concurrent chemoradiation therapy), carboplatin and paclitaxel, nivolumab
Replimune Inc., Bristol-Myers Squibb
Squamous Cell Carcinoma of Head and Neck, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
03/26
06/26
MCLA-158-CL01, NCT03526835 / 2017-004745-24: A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Recruiting
1/2
523
Europe, US
MCLA-158, petosemtamab, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX
Merus N.V., Merus N.V.
Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, NSCLC, HNSCC, Head and Neck Squamous Cell Carcinoma, Esophageal Cancer
11/25
11/27
Duravelo-1, NCT04561362 / 2020-002719-23: Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Recruiting
1/2
329
Europe, Canada, US
BT8009, Pembrolizumab, Keytruda
BicycleTx Limited
Urinary Bladder Neoplasm, Triple Negative Breast Neoplasms, Hormone Receptor Positive, HER2-negative Neoplasms, Hormone Receptor Positive, HER2-low Neoplasms, Breast Neoplasms, Non-Small-Cell Lung Neoplasms, Ovarian Neoplasm, Advanced Solid Tumor
12/26
12/26
TNG462-C101, NCT05732831: Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

Recruiting
1/2
225
Europe, US
TNG462, Pembrolizumab, Keytruda
Tango Therapeutics, Inc.
Locally Advanced Solid Tumor
05/26
09/26
Sutcliffe, Kim
SGNDV-005, NCT06003231: A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2

Recruiting
2
160
Europe, Canada, US, RoW
disitamab vedotin, RC48, RC48-ADC
Seagen Inc.
Carcinoma, Squamous Cell of Head and Neck, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Endometrial Neoplasms
05/26
05/28
BA3071-001, NCT05180799: A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

Recruiting
1/2
320
US, RoW
BA3071, Nivolumab, Pembrolizumab, Pemetrexed (Alimta)
BioAtla, Inc.
NSCLC, Melanoma
12/25
06/26
NCT04520711: Hotspot TCR-T: A Phase I/Ib Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Active, not recruiting
1
24
US
TCR-transduced T cells, CDX-1140, Pembrolizumab
Providence Health & Services
Malignant Epithelial Neoplasms
02/25
02/27
NCT05349890: Personalized TCR-T: Study of Adoptively Transferred T-cell Receptor Gene-engineered T Cells (TCR-T)

Active, not recruiting
1
1
US
TCR-transduced T cells, CDX-1140, Pembrolizumab
Providence Health & Services, Celldex Therapeutics, Providence Cancer Center, Earle A. Chiles Research Institute
Malignant Epithelial Neoplasms
04/26
04/28
Garcia, Ruth Vera
NCT05357989 / 2022-001542-38: A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Completed
3
523
Europe, US
buntanetap/posiphen, Posiphen Tartrate, ANVS401, Placebo
Annovis Bio Inc., TFS Trial Form Support
Parkinson's Disease, Idiopathic
12/23
12/23
MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting
3
400
Europe, Canada, Japan, US, RoW
tucatinib, TUKYSA, ONT-380, ARRY-380, PF-07265792, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil
Seagen Inc., Merck Sharp & Dohme LLC
Colorectal Neoplasms
08/25
04/28
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Recruiting
3
711
Europe, Canada, Japan, US, RoW
Dostarlimab, CAPEOX, FOLFOX
GlaxoSmithKline
Colonic Neoplasms, Neoplasms, Colon
12/28
12/30
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer

Recruiting
2/3
600
Europe, US, RoW
SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo
Panbela Therapeutics, Inc.
Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
08/26
01/27
Chen, Shin-Cheh
postMONARCH, NCT05169567 / 2021-002301-10: Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer

Active, not recruiting
3
368
Europe, US, RoW
Abemaciclib, Fulvestrant, Placebo
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasm, Neoplasm Metastasis
02/24
02/26
MK-2870-010, NCT06312176: A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer

Recruiting
3
1200
Europe, Canada, US, RoW
Sacituzumab tirumotecan, MK-2870, Pembrolizumab, MK-3475, KEYTRUDA®, Paclitaxel, TAXOL®, Nab-paclitaxel, ABRAXANE®, Capecitabine, XELODA®, Liposomal doxorubicin, DOXIL®
Merck Sharp & Dohme LLC
Breast Neoplasms
07/27
04/31
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
ELAINE 3, NCT05696626: Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

Recruiting
3
500
Europe, Canada, US, RoW
Lasofoxifene in combination with abemaciclib, Fulvestrant in combination with abemaciclib
Sermonix Pharmaceuticals Inc.
Metastatic Breast Cancer
04/27
04/28
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
Martinez, Alejandro
NCT04779320 / 2020-004301-31: A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)

Recruiting
3
120
Europe, Canada, Japan, US, RoW
Vedolizumab IV, ENTYVIO, KYNTELES, MLN0002
Takeda, Takeda Development Center Americas, Inc.
Crohn's Disease (CD)
11/24
11/24
 

Download Options